|
|
|
(State or Other Jurisdiction of
Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification
Number)
|
|
(Address of Principal Executive Offices) (Zip Code)
|
(
|
(Registrant’s Telephone Number, Including Area Code)
|
Not Applicable
|
(Former Name or Former Address, if Changed Since Last Report)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Emerging growth company
|
(d) Exhibits
|
|||
99.1
|
|||
99.2
|
|||
104
|
- |
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
BIO-TECHNE CORPORATION
|
|||
Date: November 2, 2021
|
By:
|
/s/ Brenda S. Furlow
|
|
Brenda S. Furlow
|
|||
Senior Vice President, General Counsel and Secretary
|
Exhibit No.
|
Description
|
99.1
|
Press Release, dated November 2, 2021, announcing results of operations
|
99.2
|
Press Release, dated November 2, 2021, announcing cash dividend.
|
104 -
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|